Quick Answer
BridgeBio Pharma, Inc. reported Stockholders Equity of -$2.09 billion for the year ending 2025.
- BridgeBio Pharma, Inc. showed a decrease of -42.1% in Stockholders Equity from 2024 to 2025.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $252.14 million | Q2 2019: $0.00 | Q2 2019: $162.93 million | Q3 2019: $459.76 million | Q1 2020: $380.72 million | Q2 2020: $265.76 million | Q3 2020: $163.76 million | Q1 2021: -$395.29 million | Q2 2021: -$464.29 million | Q3 2021: -$743.40 million | Q1 2022: -$1.04 billion | Q2 2022: -$1.03 billion | Q3 2022: -$1.14 billion | Q1 2023: -$1.23 billion | Q2 2023: -$1.36 billion | Q3 2023: -$1.21 billion | Q1 2024: -$1.05 billion | Q2 2024: -$1.09 billion | Q3 2024: -$1.23 billion | Q1 2025: -$1.65 billion | Q2 2025: -$1.79 billion | Q3 2025: -$1.93 billion.
- Over the full 10 years of available data (2016 to 2025), BridgeBio Pharma, Inc.'s Stockholders Equity has declined by 14,114.4%.
- Historical annual values: Fiscal year 2025: -$2.09 billion | Fiscal year 2024: -$1.47 billion | Fiscal year 2023: -$1.35 billion | Fiscal year 2022: -$1.25 billion | Fiscal year 2021: -$870.41 million | Fiscal year 2020: $57.91 million | Fiscal year 2019: $408.45 million | Fiscal year 2018: $314.88 million | Fiscal year 2017: $85.85 million | Fiscal year 2016: $14.89 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: